Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dronabinol Opioid Sparing Evaluation (DOSE) Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03766269
Recruitment Status : Recruiting
First Posted : December 6, 2018
Last Update Posted : December 6, 2018
Sponsor:
Information provided by (Responsible Party):
Daisy Pharma Opioid Venture, LLC

Brief Summary:
This study will be a 12-week, open-label trial that is designed to evaluate the Opioid-Sparing effect of Dronabinol at ranging doses when coadministered with the opioid analgesics that are currently being prescribed to patients for their chronic pain condition. The purpose of this trial will be to assess the effectiveness of Dronabinol when combined with opioid analgesics to relieve pain at lower opioid doses and to evaluate any reduction of opioid-related side effects. Participants will take the study-drug, Dronabinol, along with their regular prescribed opioids and the results will be evaluated and analyzed according to defined endpoints.

Condition or disease Intervention/treatment Phase
Chronic Pain Drug: Dronabinol Phase 2

Detailed Description:

Week one of the study is a Baseline Period during which time, baseline data related to opioid dose and frequency, mood, sleep, bowel movements, and pain intensity will be collected. Participants will receive no Dronabinol during week one and will continue to take their stabilized dose of regular prescribed opioids, both baseline and rescue.

Weeks two through four is the Titration Period, during which time study participants will titrate the Dronabinol dose up to a daily dose of 20 mg of Dronabinol per day, according to a prearranged titration table. Participants will continue to take their stabilized dose of regular prescribed opioids, both baseline and rescue. Participants will be encouraged to maintain the 20mg daily total dose of Dronabinol. Participants may also reduce their dose of Dronabinol at any time (if they experience severe adverse effects) to a minimum daily dose of Dronabinol of 10mg per day. Participants who cannot tolerate at least a minimum daily dose of 10mg of Dronabinol per day will be discontinued from the study.

Weeks five through twelve is the Opioid-Sparing Period, during which time participants will be encouraged to maintain the stabilized dose of Dronabinol that they "found" during the Study-Drug Dose Finding Period. Study Participants will continue to take their regular prescribed opioids, but will be encouraged to reduce their opioid dose and/or opioid dose frequency at any time during the remainder of the study should they experience a reduction in pain and/or an improvement in opioid-related side effects.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 280 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Dose-Titration Study to Evaluate the Opioid-Sparing Effect of Dronabinol When Coadministered With Opioid Analgesics to Chronic Pain Patients
Actual Study Start Date : December 1, 2018
Estimated Primary Completion Date : June 1, 2019
Estimated Study Completion Date : July 1, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Chronic Pain
Drug Information available for: Dronabinol

Arm Intervention/treatment
Baseline Opioid
One of Seven existing Baseline Opioid subgroups (Hydrocodone, Oxycodone, Morphine, Hydromorphone, Buprenorphine, Tramadol) coadministered with intervention drug, Dronabinol.
Drug: Dronabinol
Dronabinol coadministered with patient's existing Baseline Opioid.
Other Name: Marinol




Primary Outcome Measures :
  1. Pain Intensity Scale (0-10) [ Time Frame: Daily (Days 1-82) ]
    To measure the change in pain intensity from baseline using the Opioid Sparing Diary Toolkit. The measurement of the pain intensity will be derived from the Brief Pain Inventory (Short-Form) item #3. "Please rate your pain by marking the box beside the number that best describes your pain at its worst in the last 24 hours." The score is reported as a value between 0 and 10, with 0 indicative of no pain, and 10 indicative of "pain as bad as you can imagine". The score will be considered a continuous level of measurement.

  2. Self-Reported Opioid Use (Opioid Dose) [ Time Frame: Daily (Days 1-82) ]
    To measure the change in opioid dose from baseline using the Opioid Sparing Diary Toolkit

  3. Self-Reported Opioid Use Frequency (Opioid Dose Frequency) [ Time Frame: Daily (Days 1-82) ]
    To measure the change in opioid use frequency from baseline using the Opioid Sparing Diary Toolkit


Secondary Outcome Measures :
  1. Brief Pain Inventory (BPI) [ Time Frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82) ]
    To evaluate and measure any changes in pain history, intensity, location, relief, and life interference indicators from baseline

  2. Hospital and Anxiety Depression Scale (HADS) [ Time Frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82) ]
    To measure the change in depression and generalized anxiety from baseline. The HADS measures levels of anxiety and depression that a patient is experiencing. The HADS is a fourteen item scale. Seven of the items relate to a factor that measures anxiety and seven relate to a factor that measures depression. The seven items for each factor are summed into a total score and range from 0 to 21, with higher scores indicative of greater anxiety/depression. The scores will be analyzed as continuous level variables and one-sided paired-samples t-tests will be used to compare mean scores for anxiety and depression for all subjects between Week 1 (baseline) and Week 12 (EOS).

  3. Side Effect Checklist 29-item [ Time Frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82) ]
    To evaluate the presence or absence of side effects associated with the intervention

  4. RAND Health Survey 36-item [ Time Frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82) ]
    To measure the change in overall quality of life from baseline

  5. MOS Sleep Scale [ Time Frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82) ]
    To measure the change in quality of sleep from baseline. The MOS Sleep Scale Self Report includes 12 items which measure 7 individual continuous-level factors relating to sleep quality: (a) sleep disturbances, (b) snoring, (c) sleep short of breath or headache, (d) sleep adequacy, (e) sleep somnolence, (f) sleep problems index I, and (g) sleep problems index II. Each of the seven factors is scored via a two-step process such that higher resulting scores are indicative of greater sleep problems. All 7 scores are measured at the continuous level.

  6. Treatment Satisfaction Questionnaire for Medication (TSQM) [ Time Frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82) ]
    To measure the change in satisfaction with medication from baseline

  7. Bowel Function Inventory-Revised (BFI-R) [ Time Frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82) ]
    To measure the change in Opioid-Induced Constipation from baseline

  8. Current Opioid Misuse Measure (COMM) [ Time Frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82) ]
    To measure the change in Possible Opioid Misuse from baseline

  9. Numerical Opioid Side Effect (NOSE) Assessment [ Time Frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82) ]
    To measure the change in Opioid Side Effect Severity from baseline

  10. OSD: Mood Scale Self Report (0-10) [ Time Frame: Daily (Days 1-82) ]
    To measure the change in Mood from baseline. The Mood Scale is a 10 item Likert-scaled instrument with each of the 10 items scored from 1 = absolutely miserable to 10 = absolutely happy. The scores for each of the 10 items will be summed into a mood total score. The mood total score can range from 10 to 100, with higher scores indicative of happier states. The mood total score is a continuous level of measurement.

  11. OSD: Sleep Scale Self Report (0-10) [ Time Frame: Daily (Days 1-82) ]
    To measure the change in Quality of Sleep from baseline. The Sleep Scale is a 10 item Likert-scaled instrument with each of the 10 items scored from 1 = worst imaginable to 10 = best . The scores for each of the 10 items will be summed into a sleep total score. The sleep total score can range from 10 to 100, with higher scores indicative of better quality sleep. The sleep total score is a continuous level of measurement.

  12. OSD: Bowel Movement 24-Hour Self Report Survey [ Time Frame: Daily (Days 1-82) ]
    To measure the change in number of Bowel Movements from baseline

  13. FITBIT: Sleep Tracker [ Time Frame: Daily (Days 1-82) ]
    To measure the change in quantity and quality of sleep from baseline

  14. FITBIT: Distance Tracker [ Time Frame: Daily (Days 1-82) ]
    To measure the change in average weekly distance traveled from baseline

  15. FITBIT: Caloric Expenditure Tracker [ Time Frame: Daily (Days 1-82) ]
    To measure the change in average weekly calories expended from baseline

  16. Medical Billing Claims Data for each participant [ Time Frame: Study Visits 1 & 5 (Days 1 & 82) ]
    To evaluate the change in Health Care Expenditures Related To Chronic Pain from baseline (average monthly expenditures before study)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Ability to read, speak, and understand English;
  2. Provision of signed and dated informed consent form;
  3. Stated willingness to comply with all study procedures and availability for the duration of the study;
  4. Male, Female, or Transgender aged > 18;
  5. In fair and stable general health as evidenced by medical history and physical examination, and confirmed by prescriber;
  6. Participants who have been diagnosed with a pain condition that has not adequately responded to other treatments, in the judgement of the provider;
  7. Participants who are currently taking a stabilized dose of opioid analgesics, and who have been taking opioid analgesics for at least 3-months, and who report a score of > 3 on the Brief Pain Inventory 0-10 severity index.;
  8. Ability to take medications as prescribed and willingness to adhere to the study-drug regimen;
  9. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to enrollment and agreement to use such a method during study participation;
  10. Agreement to abstain from the use of cannabis or other cannabinoid compounds, other than the study-drug Dronabinol, throughout study duration;

Exclusion Criteria:

  1. Current substance abuse by self-report;
  2. Current use of cannabis or other cannabinoid compounds;
  3. Significant baseline nausea, vomiting, sedation, or other symptoms reported by physician and or patient that may compromise the collection of study-related data;
  4. A history of seizures, head trauma, and or mental illness ;
  5. Pregnancy or lactation;
  6. Known allergic reactions to components of Dronabinol;
  7. Taking any of the following drugs:

Strong CYP2C9 Inhibitor (e.g., amiodarone, fluconazole) Strong CYP3A4 Inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, erythromycin) Potent CYP2C9 or CYP3A4 inducers (e.g., rifampicin) Drugs that are highly protein-bound (e.g., warfarin, cyclosporine, amphotericin B)


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03766269


Contacts
Layout table for location contacts
Contact: Kendric B Speagle, BA 4803559000 kendric@daisyrx.com

Locations
Layout table for location information
United States, Arizona
Daisy Research, Inc. Recruiting
Scottsdale, Arizona, United States, 85255
Contact: KENDRIC B SPEAGLE, BA    480-355-9000    kendric@daisyrx.com   
Principal Investigator: Kendric B Speagle, BA         
Sponsors and Collaborators
Daisy Pharma Opioid Venture, LLC
Investigators
Layout table for investigator information
Principal Investigator: Kendric B Speagle, BA Daisy Research

Layout table for additonal information
Responsible Party: Daisy Pharma Opioid Venture, LLC
ClinicalTrials.gov Identifier: NCT03766269     History of Changes
Other Study ID Numbers: 140635
First Posted: December 6, 2018    Key Record Dates
Last Update Posted: December 6, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cannabinoid Receptor Agonists
Cannabinoid Receptor Modulators
Chronic Pain
Pain
Neurologic Manifestations
Signs and Symptoms
Analgesics, Opioid
Dronabinol
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Hallucinogens
Psychotropic Drugs
Analgesics, Non-Narcotic
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists